Content Quality: Well-structured News piece (Overview / What We Know / What We Don't Know). 606 words, appropriate for the News category (400-1200 words). Neutral, non-sensational tone throughout, including in how the boxed warning and suicide-risk language is presented.
Source Verification: Manifest at sources/2026-07/fda-approves-otsukas-simtriyo-the-first-triple-reuptake-inhibitor-for-adhd-in-adults-and-children/manifest.json lists 2 sources. source-1.html.gz (BioSpace, sha256 4fe66f1c...) is a genuine independent BioSpace news article (byline Tristan Manalac, dated July 27, 2026) and was read in full via gunzip + text extraction; it independently confirms the FDA approval, Simtriyo/centanafadine, 'first norepinephrine, dopamine, serotonin reuptake inhibitor on the U.S. market', ages 6+/20kg indication, the boxed warning (suicidal ideation/behavior risk plus abuse/misuse/addiction risk), pending DEA scheduling with 'later this year' availability, the four-Phase-3-trial claim with the adult/pediatric split and week-1-through-week-6 improvement window, and the Jefferies analyst quotes ('important de-risking event', 'marks the arrival of Otsuka's next major CNS launch', '~$615 million' peak sales forecast, 'large and under-penetrated' market, 'well positioned to address patients seeking alternatives to traditional stimulant therapies') near-verbatim. source-0.html.gz (nominally Yahoo Finance/Business Wire, sha256 caca88d7...) turned out on decompression to be entirely a German-language GDPR consent-wall page ('Ihre Datenschutzeinstellungen') with zero occurrences of Simtriyo, centanafadine, Kraus, Adler, or ADHD — the manifest's own 'redirected_domain: consent.yahoo.com' flag corroborates this. Since the archived snapshot for this source was functionally unusable (equivalent to a failed fetch despite HTTP 200), I fetched the live URL directly via curl with a browser User-Agent (bypassing the cookie-consent redirect our snapshot fetcher hit) and independently confirmed, by direct string search over the raw extracted text (not by trusting an LLM-mediated summary), that the Business Wire press release (dateline 'PRINCETON, N.J. & TOKYO, July 25, 2026 --(BUSINESS WIRE)--') verbatim contains: the John Kraus quote ('The approval of SIMTRIYO marks an important milestone for people living with ADHD, as it introduces a novel treatment approach for this condition'), the Lenard A. Adler/NYU Langone quote ('having more therapeutic choices is important because ADHD is a highly individualized condition and treatment decisions should reflect the unique needs of each patient'), the CDC prevalence figures (7 million children, 15.5 million adults, ~22.5 million combined), the boxed-warning age qualifier ('Higher rates of suicidal ideation and behaviors occurred in Simtriyo-treated patients aged 6 to 12 years... than in placebo-treated patients'), the abuse/misuse/addiction warning language, the exact rating-scale names (ADHD Rating Scale-5 / ADHD-RS-5 for pediatric, Adult ADHD Investigator Symptom Rating Scale / AISRS for adults), and the four-Phase-3-trial description with NCT identifiers. One discrepancy found in this process: the source differentiates adverse events by pediatric age band (rash + decreased appetite only for ages 6-12; the fuller five-symptom list for ages 13-17), but the submission's body_markdown collapses both bands into one 'children and adolescents' bucket using the fuller list — filed as a correction (see findings). A second minor issue, not filed as a correction: the article's 'What We Don't Know' section states trial identifiers were 'not detailed in the sources reviewed,' but the Business Wire release does include NCT numbers (NCT03605680, NCT03605836, etc.) — an overly cautious hedge rather than a false claim, so no reader-facing correction is warranted for it.
Factual Accuracy: All direct quotes verified verbatim against the primary source. The CDC prevalence statistic (7M children + 15.5M adults = 22.5M) is arithmetically consistent and matches the source exactly. The mechanism description ('blocking the reuptake of norepinephrine, dopamine, and serotonin...') is a fair paraphrase of the source's mechanism language and is not presented as a direct quote. The 'first triple-reuptake inhibitor for ADHD' / NDSRI claim, the boxed warning, the pending DEA scheduling, and the Jefferies commentary are all independently corroborated by BioSpace, a genuine secondary journalistic source (not merely a press-release mirror). The single confirmed inaccuracy is the adverse-event age-band conflation described above.
Overall Assessment: Substantively accurate, well-sourced, neutral News piece on a genuine FDA approval story. Every direct quote, statistic, and named-source attribution was independently verified against the primary press release (fetched live after the archived snapshot for that source turned out to be a cookie-consent wall) and corroborated by an independent BioSpace report. One recoverable, body-text-only inaccuracy (conflating two pediatric adverse-event age bands) warrants a public corrections note; nothing here rises to a headline/lead-level problem or a pattern of fabrication, so APPROVE_WITH_CORRECTIONS rather than REJECT.